The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 16, 2023
Filed:
Mar. 08, 2019
The Usa, As Represented BY the Secretary, Dept. of Health and Human Services, Bethesda, MD (US);
Pontificia Universidad Católica DE Chile, Santiago, CL;
Juan J. Marugan, Gaithersburg, MD (US);
Marc Ferrer, Potomac, MD (US);
Noel T. Southall, Potomac, MD (US);
Andres E. Dulcey, Gaithersburg, MD (US);
Xin Hu, Frederick, MD (US);
Christopher R. Dextras, Frederick, MD (US);
Daniel C. Talley, Baltimore, MD (US);
Alejandra Alvarez, Santiago, CL;
Silvana Zanlungo, Santiago, CL;
Rommy M. Von Bernhardi, Santiago, CL;
The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Pontificia Universidad Catolica de Chile, Santiago, CL;
Abstract
Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as 'c-Abl'). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.